Literature DB >> 21846854

Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease.

Asaf Vivante1, Arnon Afek, Yael Frenkel-Nir, Dorit Tzur, Alon Farfel, Eliezer Golan, Yoram Chaiter, Tamy Shohat, Karl Skorecki, Ronit Calderon-Margalit.   

Abstract

CONTEXT: Few data are available on long-term outcomes among adolescents and young adults with persistent asymptomatic isolated microscopic hematuria.
OBJECTIVE: To evaluate the risk of end-stage renal disease (ESRD) in adolescents and young adults with persistent asymptomatic isolated microscopic hematuria. DESIGN, SETTING, AND PARTICIPANTS: Nationwide, population-based, retrospective cohort study using medical data from 1,203,626 persons aged 16 through 25 years (60% male) examined for fitness for military service between 1975 and 1997 were linked to the Israeli treated ESRD registry. Incident cases of treated ESRD from January 1, 1980, to May 31, 2010, were included. Cox proportional hazards models were used to estimate the hazard ratio (HR) of treated ESRD among those diagnosed as having persistent asymptomatic isolated microscopic hematuria. MAIN OUTCOME MEASURES: Treated ESRD onset, defined as the date of initiation of dialysis treatment or the date of renal transplantation, whichever came first.
RESULTS: Persistent asymptomatic isolated microscopic hematuria was diagnosed in 3690 of 1,203,626 eligible individuals (0.3%). During 21.88 (SD, 6.74) years of follow-up, treated ESRD developed in 26 individuals (0.70%) with and 539 (0.045%) without persistent asymptomatic isolated microscopic hematuria, yielding incidence rates of 34.0 and 2.05 per 100,000 person-years, respectively, and a crude HR of 19.5 (95% confidence interval [CI], 13.1-28.9). A multivariate model adjusted for age, sex, paternal country of origin, year of enrollment, body mass index, and blood pressure at baseline did not substantially alter the risk associated with persistent asymptomatic isolated microscopic hematuria (HR, 18.5 [95% CI, 12.4-27.6]). A substantially increased risk for treated ESRD attributed to primary glomerular disease was found for individuals with persistent asymptomatic isolated microscopic hematuria compared with those without the condition (incidence rates, 19.6 vs 0.55 per 100,000 person-years, respectively; HR, 32.4 [95% CI, 18.9-55.7]). The fraction of treated ESRD attributed to microscopic hematuria was 4.3% (95% CI, 2.9%-6.4%).
CONCLUSION: Presence of persistent asymptomatic isolated microscopic hematuria in persons aged 16 through 25 years was associated with significantly increased risk of treated ESRD for a period of 22 years, although the incidence and absolute risk remain quite low.

Entities:  

Mesh:

Year:  2011        PMID: 21846854     DOI: 10.1001/jama.2011.1141

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  63 in total

Review 1.  The living kidney donor evaluation: focus on renal issues.

Authors:  Ajay Kher; Didier A Mandelbrot
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

2.  Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy.

Authors:  Miho Tatematsu; Yoshinari Yasuda; Yoshiki Morita; Izumi Sakamoto; Kei Kurata; Tomohiko Naruse; Rhohei Yamamoto; Naotake Tsuboi; Waichi Sato; Enyu Imai; Seiichi Matsuo; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2012-05-23       Impact factor: 2.801

3.  Glomerular isolated microscopic hematuria: urinary features and long term follow-up of a selected cohort of patients.

Authors:  Cecilia Bellincioni; Giuseppe Garigali; Giovanni B Fogazzi
Journal:  J Nephrol       Date:  2018-12-10       Impact factor: 3.902

4.  Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994-2011.

Authors:  Dita Maixnerova; Eva Jancova; Jelena Skibova; Romana Rysava; Ivan Rychlik; Ondrej Viklicky; Miroslav Merta; Alexander Kolsky; Jana Reiterova; Michaela Neprasova; Jana Kidorova; Eva Honsova; Vladimir Tesar
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

5.  Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker.

Authors:  Rosanna Coppo; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

6.  Japanese guidelines of the management of hematuria 2013.

Authors:  Shigeo Horie; Shuichi Ito; Hirokazu Okada; Haruhito Kikuchi; Ichiei Narita; Tsutomu Nishiyama; Tomonori Hasegawa; Hiroshi Mikami; Kunihiro Yamagata; Tomoji Yuno; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2014-10       Impact factor: 2.801

Review 7.  Pathogenesis of glomerular haematuria.

Authors:  Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno
Journal:  World J Nephrol       Date:  2015-05-06

8.  Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

Authors:  Angel M Sevillano; Eduardo Gutiérrez; Claudia Yuste; Teresa Cavero; Evangelina Mérida; Paola Rodríguez; Ana García; Enrique Morales; Cristina Fernández; Miguel Angel Martínez; Juan Antonio Moreno; Manuel Praga
Journal:  J Am Soc Nephrol       Date:  2017-06-07       Impact factor: 10.121

9.  Persistent asymptomatic isolated hematuria in children: clinical and histopathological features and prognosis.

Authors:  Chun-Yue Feng; Yong-Hui Xia; Wen-Jin Wang; Jin Xia; Hai-Dong Fu; Xia Wang; Hui-Jun Shen; Gu-Ling Qian; Ai-Min Liu; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2013-05-16       Impact factor: 2.764

10.  The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy.

Authors:  Seung Seok Han; Seung Hee Yang; Murim Choi; Hang-Rae Kim; Kwangsoo Kim; Sangmoon Lee; Kyung Chul Moon; Joo Young Kim; Hajeong Lee; Jung Pyo Lee; Ji Yong Jung; Sejoong Kim; Kwon Wook Joo; Chun Soo Lim; Shin-Wook Kang; Yon Su Kim; Dong Ki Kim
Journal:  J Am Soc Nephrol       Date:  2016-04-11       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.